Financial Performance - The Group's revenue reached RMB 131,867 million, a YoY increase of 2.5%[11] - Gross profit increased to RMB 21,510 million, representing a YoY growth of 2.8%[11] - Net profit attributable to shareholders decreased significantly by 20.3% to RMB 2,077 million[11] - Operating cash flow significantly improved, reaching RMB 1,531 million, a YoY increase of 250.1%[11] Business Segments - Pharmaceutical manufacturing business revenue increased by 4.3% YoY to RMB 24.81 billion[20] - Distribution business revenue increased by 2.3% YoY to RMB 108,330 million[63] - Retail business revenue increased by 11.4% YoY to RMB 5,515 million[63] Strategic Initiatives - The Group completed the acquisitions of Nigale and Tasly to expand into medical devices and TCM, respectively[24] - The Group is committed to innovative R&D with 476 total projects under research and development[37] - The Group is strengthening international expansion of chemical drugs, TCM, medical devices and blood products[54] - The Group introduced 7 new medical device products, with estimated annual revenue contribution of over RMB 600 million[73]